ERYTHROPOIETIN

Other

Brand names: PROCRIT

Intravenous, Subcutaneous

Mechanism of Action

12.1 Mechanism of Action PROCRIT stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.

Indications

and upon initiation

there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective

noncardiac

nonvascular surgery ( 1.4 ). Limitations of Use PROCRIT has not been shown to improve quality of life

fatigue

or patient well-being ( 1.5 ). PROCRIT is not indicated for use: In patients with cancer receiving hormonal agents

Contraindications

• infants
• pregnant women
• and lactating women [see Warnings and Precautions (5.9)
• Use in Specific Populations (8.1
• 8.2

FDA Warnings

5 WARNINGS AND PRECAUTIONS Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism: Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit ( 5
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer ( 5
Seizures: PROCRIT increases the risk for seizures in patients with CKD ( 5
Serious Allergic Reactions: Discontinue PROCRIT and manage reactions ( 5

Known Side Effects

8 documented side effects by frequency

Fatigue

1-10%

Weakness

1-10%

Diarrhea

1-10%

Nausea

1-10%

Shortness of Breath

1-10%

Drug Not Working

0.1-1%

Vomiting

0.1-1%

Fever

0.1-1%

Community Discussions

No community discussions found for ERYTHROPOIETIN yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous, Subcutaneous